Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus RIVASTIGMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus RIVASTIGMINE.
EDROPHONIUM CHLORIDE vs RIVASTIGMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Reversible acetylcholinesterase inhibitor that enhances cholinergic function by increasing the concentration of acetylcholine at synaptic sites. Also inhibits butyrylcholinesterase.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
1.5 mg orally twice daily initially, titrated by 1.5 mg/dose every 2 weeks to maintenance dose of 3-6 mg twice daily. Alternatively, transdermal patch: 4.6 mg/24h initially, titrate to 9.5 mg/24h after 4 weeks, then 13.3 mg/24h if tolerated.
None Documented
None Documented
Clinical Note
moderateRivastigmine + Dronedarone
"Rivastigmine may increase the bradycardic activities of Dronedarone."
Clinical Note
moderateRivastigmine + Nicotine
"The risk or severity of adverse effects can be increased when Rivastigmine is combined with Nicotine."
Clinical Note
moderateRivastigmine + Amiodarone
"Rivastigmine may increase the bradycardic activities of Amiodarone."
Clinical Note
moderateRivastigmine + Crizotinib
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal half-life ~1.5 h (oral, transdermal); clinical context: due to prolonged binding to acetylcholinesterase (AChE), effective half-life for AChE inhibition is ~10 h; steady state reached in 6-12 weeks.
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Renal: ~97% total (mostly metabolites, <1% unchanged); fecal: negligible; biliary: minor.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor
"Rivastigmine may increase the bradycardic activities of Crizotinib."